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Background: Abnormal morphologic variability (MV), a recently proposed risk metric measuring subtle variability in the shape of ECG signals, is 
associated with increased 90 day and 365 day mortality post-NSTEACS. This study evaluates the association of MV with ventricular tachycardia (VT) 
and ventricular pause (VP) in the days immediately following NSTEACS.
Methods: MV was measured in 4557 patients in the MERLIN-TIMI 36 trial using the first 24 hours of continuous ECG after randomization. Patients 
were divided into high (MV>52.5) and low (MV<=52.5) MV groups using a pre-specified cutoff. The endpoints for the analysis were VT >= 8 beats in 
length and VP >= 3 seconds detected on continuous ECG data after MV was assessed (median duration 5.8 days).
Results: Patients with high MV were at a higher risk of both VT (OR 1.56, p=0.011) and VP (OR 2.57, p<0.001), which was consistent even after 
adjusting for the TIMI risk score (adjusted OR for VT 1.50, p=0.035; for VP 2.17, p=0.002). High MV was associated with an increased risk of both VT 
and VP in the placebo group, and an increased risk of VP in patients assigned to ranolazine (Table).
Conclusions: Our results suggest that patients with high MV are at an increased risk of developing significant arrhythmias in the days immediately 
following NSTEACS. MV may therefore be clinically useful in identifying patients requiring more intense monitoring or therapy. The risk of VT 
associated with high MV may be attenuated by ranolazine. 
Group Endpoint
Incidence of Arrhythmia
Odds Ratio 95% CI P Value
High MV (%)
Low MV
(%)
All 
(n=4557)
VT 5.3 3.5 1.6 1.1-2.2 0.011
VP 3.6 1.4 2.6 1.7-4.0 <0.001
Placebo
(n=2302)
VT 7.4 3.9 2.0 1.3-2.9 0.001
VP 3.2 1.7 2.0 1.1-3.6 0.033
Ranolazine
(n=2255)
VT 2.6 3.0 0.9 0.4-1.7 0.656
VP 4.2 1.2 3.5 1.8-6.7 <0.001
